- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01812616
A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients
December 19, 2022 updated by: Jazz Pharmaceuticals
A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma
An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A).
A randomisation phase to assess the safety of Sativex compared with placebo (Part B).
Part B will be reported here.
Study Overview
Detailed Description
Patients will receive Sativex and dose-intense Temozolomide in an open-label phase.
The incidence of adverse events will be monitored (Part A).
An investigator led Safety Review Team will assess the safety profile of the open-label patients and decide whether the study can progress to the randomisation phase (Part B).
Patients who enrol in the randomisation phase patients will receive either Sativex or placebo.
The safety of Sativex compared to placebo will be assessed by pharmacokinetic analysis of Temozolomide and its metabolites, clinical laboratory tests, adverse events and vital signs.
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aachen, Germany, 52074
- Klinik für Onkologie, Hämatologie und Stammzelltransplantation, Universitätsklinikum Aachen RWTH
-
Altenburg, Germany, 04600
- Neurologie des Klinikums Altenburger Land
-
Duesseldorf, Germany, 40225
- Zentrum für Neuroonkologie der Universität Duesseldorf
-
Erlangen, Germany, 91054
- Strahlenklinik der Universität Erlangen
-
-
-
-
-
Bristol, United Kingdom, BS2 8ED
- Bristol Haematology & Oncology Centre
-
Cottingham, United Kingdom, HU16 5JQ
- Queen's Centre for Haematology & Oncology, Castle Hill Hospital
-
Glasgow, United Kingdom, G12 0YN
- West of Scotland Beatson Cancer Centre
-
London, United Kingdom, SE1 7EH
- Guy's & St Thomas' NHS Foundation Trust, of St Thomas' Hospital
-
Manchester, United Kingdom, M20 4BX
- The Christie Nhs Foundation Trust
-
-
Wirral
-
Bebington, Wirral, United Kingdom, CH63 4JY
- The Clatterbridge Cancer Centre NHS Foundation Trust
-
-
Yorkshire
-
Leeds, Yorkshire, United Kingdom, LS9 7TF
- St James's Institute of Oncology, St James's University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is willing and able to give informed consent for participation in the study.
- Patient is aged 18 years or above.
- Histopathologically confirmed diagnosis of grade four Glioblastoma Multiforme as per World Health Organisation classification.
- Evidence of patients first tumour progression (as determined by Revised Assessment in Neuro-Oncology) following radiation and first line chemotherapy with Temozolomide.
- If taking steroids, then the dose must be stable or decreasing.
- Karnofsky performance scale of 60% or greater.
- Patient is able (in the investigators opinion) and willing to comply with all study requirements.
- Patient is willing for his or her name to be notified to the responsible authorities for participation in this study, as applicable in individual countries.
- Patient is willing to allow his or her primary care practitioner and consultant, if appropriate, to be notified of participation in the study.
Exclusion Criteria:
- Patients with Glioblastoma Multiforme secondary to low-grade glioma or anaplastic glioma (anaplastic astrocytoma or anaplastic oligodendroglioma).
- Patients currently receiving treatment for recurrent Glioblastoma Multiforme.
- Less than a four week interval since prior chemotherapy.
- Less than a 12 week interval since prior radiotherapy unless there is either: a) histopathology confirmation of recurrent tumour, or b) new enhancement on Magnetic Resonance Imaging outside of the radiotherapy treatment field.
- Presence of extra-cranial metastatic disease.
- Any surgery, including intracranial biopsy (not including minor diagnostic procedures such as lymph node biopsy) within two weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures.
- Any history of a different malignancy unless the patient has remained disease-free for at least three years and are at low risk for recurrence of that malignancy (cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin are exempt from this criterion if treatment has occurred).
- Have previously received first line chemotherapy other than Temozolomide.
- Presents with Leptomeningeal dissemination.
- Have previously received stereotactic radiotherapy, convection enhanced delivery or brachytherapy (as gliosis/scarring from these modalities may limit delivery).
- The patient is currently using or has used cannabis or cannabinoid based medications within 30 days of study entry and is unwilling to abstain for the duration of the study.
- Any known or suspected history of a substance abuse/dependence disorder, current heavy alcohol consumption (>60g of pure alcohol per day for men, >40 g of pure alcohol per day for women), current use of an illicit drug or current non prescribed use of any prescription drug.
- Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
- Has experienced myocardial infarction or clinically significant dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the patient at risk of clinically significant arrhythmia or myocardial infarction.
- Has grade 3 or above toxicity by Common Terminology Criteria for Adverse Events criteria.
- Female patients of child bearing potential and male patients whose partner is of child bearing potential, unless willing to ensure that they or their partner use effective contraception, for example, oral contraception, double barrier, intra-uterine device, during the study and for three months thereafter (however a male condom should not be used in conjunction with a female condom).
- Female patients who are pregnant, lactating or planning pregnancy during the course of the study and for three months thereafter.
- Patient who have received an Investigational Medicinal Product within the four weeks prior to the screening visit.
- Any other significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the result of the study, or the patient's ability to participate in the study.
- Travel outside the country of residence planned during the study.
- Patients previously enrolled into this study and received either Investigational Medicinal Product or Dose-Intense Temozolomide.
- Any known or suspected hypersensitivity to cannabinoids or any of the excipients of the Investigational Medicinal Product.
- Any known allergy to or other intolerability to Temozolomide.
- Following a physical examination, the patient has any abnormalities that, in the opinion of the investigator would prevent the patient from safe participation in the study.
- Unwilling to abstain from donation of blood during the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sativex and Dose-Intense Temozolomide
Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
|
Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day).
Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
Other Names:
|
Placebo Comparator: Placebo and Dose-Intense Temozolomide
Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
|
Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day).
Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Adverse Events as a Measure of Patient Safety.
Time Frame: Study Day 1 - Day 358
|
Adverse events will be coded according to the current medical dictionary for regular activities graded using the Common Terminology Criteria for Adverse Events criteria.
The number of patients who experienced an adverse event whilst on treatment will be presented.
|
Study Day 1 - Day 358
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The number of patients with Progression Free Survival at six months (PFS6)
Time Frame: Study Day 1 - Day 190
|
PFS6 will be assessment at Visit 11 (Day 190).
Progression of disease will be determined from Response Assessment in Neuro-Oncology tumour assessment (based on Magnetic Resonance Imaging scans).
The number of patients with PFS6 will be presented for the individual treatment groups.
|
Study Day 1 - Day 190
|
Overall Survival
Time Frame: Study Day 1 - Day 358
|
Overall survival will be assessed at the end of the treatment visit (Day 358 or at early termination).
The number of surviving patients in each group from the randomisation phase (Part B) will be presented.
|
Study Day 1 - Day 358
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
March 14, 2013
First Submitted That Met QC Criteria
March 14, 2013
First Posted (Estimate)
March 18, 2013
Study Record Updates
Last Update Posted (Actual)
December 20, 2022
Last Update Submitted That Met QC Criteria
December 19, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Nabiximols
Other Study ID Numbers
- GWCA1208 Part B
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Sativex
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity Disorder (ADHD)United Kingdom
-
AbbottRecruiting
-
Mary LynchCompleted
-
S. Andrea HospitalUniversity of Roma La SapienzaUnknown
-
Jazz PharmaceuticalsQuintiles, Inc.CompletedPain | Cancer | Palliative CareSpain, United Kingdom, United States, Canada, Poland, India, France, Czech Republic, Belgium, Romania, Chile, Finland, Germany, Italy, Mexico, South Africa
-
Jazz PharmaceuticalsCompleted
-
National Institute on Drug Abuse (NIDA)CompletedPharmacokinetics | Cannabis | Dependence | Cannabis Abuse | fMRIUnited States
-
Almirall, S.A.CompletedMultiple SclerosisItaly
-
Michael, Levy M.D.,Ph.D.Jazz PharmaceuticalsNot yet recruitingSpasticity, Muscle | NMO Spectrum DisorderUnited States
-
One World Cannabis Ltd.Completed